Abduloeva Nuriniso Khamdulloevna (Candidate of Medicine, Deputy Director for Outpatient Work of the State Medical Institution «St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov»)
Moiseenko Vladimir Mikhailovich (Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Director St. Petersburg Clinical Research and Practical Center of Specialized Types for Medical Care (Oncological) named after N. P. Napalkov)
Skripko Olga Aleksandrovna (Oncologist of the polyclinic department State Medical Institution «St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov».)
Sheraliev Aslan Rakhimdzhonovich (Candidate of Medicine, oncologist of the polyclinic department State Medical Institution «St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov».)
Zhabina Albina Sergeevna (Candidate of Medicine, Physician of Chemotherapy Department, St. Petersburg Clinical Research and Practical Center of Specialized Types for Medical Care (Oncological))
| |
The combination of CDK 4/6 inhibitors (iCDK 4/6) with endocrine therapy improves progression-free and overall survival in patients with luminal HER2-negative metastatic breast cancer (mBC). However, the efficacy of abemaciclib combined with subsequent hormone therapy (HT) after progression on iCDK 4/6 remains unexplored.
A retrospective analysis was conducted on 100 patients with luminal HER2-negative mBC who received either HT with abemaciclib (n=49) or HT alone (n=51) after progression on iCDK 4/6 at the N.P. Napalkov St. Petersburg Clinical Oncology Center from 01.01.2022 to 31.12.2023. All patients had previously received palbociclib (53%) or ribociclib (47%) in combination with HT.
Median PFS in the HT + abemaciclib group was 12±1.13 months (95% CI 9.77–14.22), compared to 9±0.28 months (95% CI 8.45–9.54) in the HT-alone group (HR=0.486; 95% CI 0.301–0.784, p=0.003), demonstrating a significant benefit of the combination approach.
The addition of abemaciclib to HT improves PFS in patients with mBC after progression on other iCDK 4/6 inhibitors (palbociclib or ribociclib).
Keywords:iCDK 4/6, progression, abemaciclib, mBC.
|
|
| |
|
Read the full article …
|
Citation link:
Abduloeva N. K., Moiseenko V. M., Skripko O. A., Sheraliev A. R., Zhabina A. S. ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY AFTER PROGRESSION ON CDK 4/6 INHIBITORS IN HR+HER2– METASTATIC BREAST CANCER // Современная наука: актуальные проблемы теории и практики. Серия: Естественные и Технические Науки. -2025. -№05. -С. 193-198 DOI 10.37882/2223-2966.2025.05.01 |
|
|
